Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective ...
Physician's Weekly4 小时
Ophthalmic Manifestations and Genetic Variants in VEXAS Syndrome
The following is a summary of “Ocular features of VEXAS syndrome: a systematic review and meta-analysis,” published in the ...
Pharmabiz9 小时
Bayer, Puhe BioPharma ink global license agreement for clinical phase I PRMT5 inhibitor
Bayer, Puhe BioPharma ink global license agreement for clinical phase I PRMT5 inhibitor: Berlin, Germany Friday, March 28, 2025, 13:00 Hrs [IST] Bayer and Suzhou Puhe BioPharma Co ...